Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers.
Latest Information Update: 06 Jan 2021
At a glance
- Drugs Everolimus (Primary)
- Indications Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Stent thrombosis
- Focus Therapeutic Use
- Acronyms AIDA
Most Recent Events
- 01 Sep 2020 Results of pooled analysis from COMPARE-ABSORB and AIDA presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 01 Sep 2020 Results assessing value of prolonged DAPT against scaffold thrombosis, presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology.
- 01 Sep 2020 Results of pooled analysis from COMPARE-ABSORB and AIDA presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology